Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

News

AstraZeneca publish primary analysis from US trial of coronavirus vaccine

Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.

Marking 100 years of the tuberculosis BCG vaccine

The VALIDATE Network, a community of over 400 researchers based in more than 200 research institutions in 63 countries, will today launch the “BCG100 Programme” marking the centenary of the Bacille Calmette-Guérin Vaccine for tuberculosis. BCG100 officially launches with the ‘BCG Then and Now’ online lecture by Professor Helen McShane, VALIDATE Network Director and Jenner Investigator and Professor Paul Fine, London School of Hygiene and Tropical Medicine. Taking place at 6pm GMT, 24 March 2021, the talk will cover the initial development of the vaccine, moving through to the modern-day challenges in the fight against TB and the future challenges researchers face in replacing the enduring BCG vaccine.

USA, Chile and Peru interim trial data show Oxford-AstraZeneca vaccine is safe and highly effective

A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom.

Existing vaccines may protect against the Brazilian coronavirus variant

Scientists at the University of Oxford have released pre-print data measuring the level of antibodies that can neutralise – or stop infection from – variants that are circulating in South Africa, Brazil and elsewhere. These data suggest that natural- and vaccine-induced antibodies can still neutralise these variants, but at lower levels. Importantly, the P1 ‘Brazilian’ strain may be less resistant to these antibodies than first feared.

COVID OUTBREAK

During the COVID-19 pandemic, the Jenner Institute is taking measures to prevent the spread of the disease. Departments are instructed by the University’s Registrar to continue to work from home where possible, and manage the return to on site working, based on the University guidelines for risk assessments and work prioritisation. This is to restrict contact between individuals as far as possible. The University remains open and operating as far as possible with the following restrictions:

- No public access to the University.

- On-site activity permitted where it cannot be undertaken remotely, driven by safety, capacity and other factors such as schools reopening/other changes in government guidelines.

- Teaching and assessment are undertaken remotely where possible and, depending on government guidelines, gatherings of staff and students only permitted where essential for teaching and assessment to take place.

UPDATE ON COVID-19 VACCINE Trial

For all information and enquiries regarding the COVID-19 vaccine trial, please visit: https://covid19vaccinetrial.web.ox.ac.uk/.

Public Engagement